This article is more than 5 years old. Information may no longer be current.

Allergan reports year-end earnings

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Allergan announced year-end net sales of $2.32 billion in 2005, an increase from the $2.04 billion it earned in 2004, the company said in a press release. Net earnings for the year were $385.8 million, increased from $377.1 million in 2004, the company added.

Eye care pharmaceuticals generated $1.32 billion during 2005, an increase of 16.2% from 2004 levels. Botox (botulinum toxin) sales increased almost 18% from 2004 with a total $830.9 million in sales. Allergan’s skin care line generated $120.2 million during the year, an increase of 16.2% from 2004 levels, the company said in its release.

Glaucoma drugs Alphagan P (brimonidine tartrate), Alphagan (brimonidine 0.2%) and Combigan (0.1% brimonidine tartrate, 0.5% timolol maleate) led sales, totaling $277.2 million for the year. Lumigan (bimatoprost ophthalmic solution 0.03%) sales were $267.6 million for the year, with other glaucoma drugs totaling $18 million. Dry eye treatment Restasis (cyclosporine) posted sales of $190.9 million for the year.

Highlights for the company during the fourth quarter included entering into a long-term agreement with GlaxoSmithKline to develop and promote Botox in Japan and China. In November, the company agreed to acquire Inamed Corp. for $84 a share or for a share of Allergan stock. The company has extended the tender offer until Feb. 22, 2006.